OncoMatch/Clinical Trials/NCT05580601
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
Is NCT05580601 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CIML-NK Cells for acute myeloid leukemia.
Treatment: CIML-NK Cells — The objective of this study is to demonstrate that cytokine-induced memory-like natural killer cells can be generated from donor cells and infused safely into patients with relapsed or refractory acute myeloid leukemia (AML). A secondary objective is to assess efficacy of the CIML-NK cells in treating AML.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Disease stage
Required: Stage RELAPSED, REFRACTORY
Excluded: Stage ISOLATED CENTRAL NERVOUS SYSTEM (CNS) DISEASE, ISOLATED EXTRAMEDULLARY DISEASE
With relapsed or refractory AML in their bone marrow; Disease: isolated central nervous system (CNS) disease, or isolated extramedullary disease, or diagnosis of acute promyelocytic leukemia (APML) [excluded].
Lab requirements
Liver function
total bilirubin > 2mg/dl, ast and alt more than three times the upper limit of normal [excluded]
Cardiac function
systolic ejection fraction <45% by echocardiogram [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cincinnati Children's Hospital Medical Center · Cincinnati, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify